+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Almirall SA (ALM) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 66 Pages
  • May 2026
  • GlobalData
  • Almirall, S.A.
  • ID: 4308187
Almirall SA (ALM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Almirall SA (Almirall) is a pharmaceutical company. The company's main activities include the development, production, and marketing of medical solutions for dermatological conditions such as psoriasis, atopic dermatitis, acne, and actinic keratosis. It also develops and markets general medicine and OTCs related to the central nervous, cardiovascular, dermatology, gastrointestinal, and musculoskeletal systems. Almirall collaborates with strategic partners and operates through a network of local sales networks, licensees, third-party manufacturing, and intermediaries to distribute its products. The company's products are used by healthcare professionals to treat patients through brands such as Ilumetri, Wynzora, and Skilarence. The company has business presence in Europe, the Middle East, the Americas, Asia, and Africa. Almirall is headquartered in Barcelona, Spain.

Almirall SA Key Recent Developments

  • May 11, 2026: Almirall Reports Q1 2026 Growth Driven by European Dermatology Business
  • May 11, 2026: Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations - Led by 19.3% Yoy Growth of Its European Dermatology Business
  • May 04, 2026: Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
  • Apr 13, 2026: Almirall and Barcelona Supercomputing Center Expand Collaboration to Accelerate Medical Dermatology Innovation

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Almirall SA - Key Facts
  • Almirall SA - Key Employees
  • Almirall SA - Key Employee Biographies
  • Almirall SA - Major Products and Services
  • Almirall SA - History
  • Almirall SA - Company Statement
  • Almirall SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Almirall SA - Business Description
  • Business Segment: Marketing Through its own Network
  • Overview
  • Performance
  • Business Segment: Marketing Through Licensees
  • Overview
  • Performance
  • Business Segment: Third-party Manufacturing and Intermediation
  • Overview
  • Performance
  • Geographical Segment: America, Asia and Africa
  • Performance
  • Geographical Segment: Europe and Middle East
  • Performance
  • Geographical Segment: Spain
  • Performance
  • R&D Overview
  • Almirall SA - Corporate Strategy
  • Almirall SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Almirall SA - Strengths
  • Almirall SA - Weaknesses
  • Almirall SA - Opportunities
  • Almirall SA - Threats
  • Almirall SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Almirall SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 11, 2026: Almirall Reports Q1 2026 Growth Driven by European Dermatology Business
  • May 11, 2026: Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations - Led by 19.3% Yoy Growth of Its European Dermatology Business
  • May 04, 2026: Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
  • Apr 13, 2026: Almirall and Barcelona Supercomputing Center Expand Collaboration to Accelerate Medical Dermatology Innovation
  • Mar 27, 2026: Lebrikizumab Provides Up to Four Years of Disease Control in Moderate-to-Severe Atopic Dermatitis
  • Mar 26, 2026: Almirall Presents Clinical and Real-World Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
  • Mar 26, 2026: AAD 2026: Almirall Presents New Clinical and Real-World Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
  • Mar 23, 2026: Almirall's 17th Skin Academy Highlights Advances in Inflammatory Skin Diseases, Skin Cancer, Patient-Reported Outcomes, and Holistic Care
  • Mar 23, 2026: Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology
  • Mar 16, 2026: Lebrikizumab Achieves Significant Skin Clearance and Disease Improvement in Children With Moderate-to-Severe Atopic Dermatitis
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Almirall SA, Key Facts
  • Almirall SA, Key Employees
  • Almirall SA, Key Employee Biographies
  • Almirall SA, Major Products and Services
  • Almirall SA, History
  • Almirall SA, Subsidiaries
  • Almirall SA, Key Competitors
  • Almirall SA, Ratios based on current share price
  • Almirall SA, Annual Ratios
  • Almirall SA, Interim Ratios
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Almirall SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Almirall SA, Performance Chart (2021-2025)
  • Almirall SA, Ratio Charts
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Laboratorios Farmaceuticos Rovi SA
  • Laboratorios Richmond SACIF
  • Esteve Pharmaceuticals SA
  • Laboratorio CIFGA SA
  • ALK-Abello AS
  • Faes Farma SA